HCM.L StockTwits Mentions

Track HCM.L's AI-powered predictions, market trends, and investment insights.

HCM.L AI Prediction HCM.L Sentiment HCM.L Reddit

Mock Tradesimulated, no real money

You don't hold HCM.L in your mock portfolio yet.

HCM.L StockTwits Mentions

Track HCM.L's AI-powered predictions, market trends, and investment insights.

HCM.L AI Prediction HCM.L Sentiment HCM.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-2.5%

Price (7d)2.2%

Volume vs avg0.7x

Volatility vs normal0.4x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 46K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$161.50 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

HCM.L AI Stock Analysis

Financial Performance

neutral

The company is profitable on an earnings-per-share basis, with a very low PE ratio suggesting the market is heavily discounting its earnings sustainability or growth prospects. EPS of 0.40 at a $165 share price implies a PE of about 412, so the stated 4.12 PE likely reflects either different currency/denominator conventions or a data inconsistency. Overall, the numbers point to a profitable but market-discounted business where investors are skeptical about future earnings durability.

Positive EPS (0.40) indicates the company is generating net income rather than losses, a basic but important sign of financial health in a sector where many peers are loss-making.
The quoted PE ratio of 4.12 is extremely low for a healthcare/biopharma name and typically signals either deep value, perceived high risk, or questions about the quality/sustainability of earnings.
The disconnect between price ($165), EPS (0.40), and the stated PE suggests investors should verify the underlying financials (currency, share count, and one-off items) before drawing strong conclusions from headline valuation metrics.

Stock Price & Technicals

bearish

The stock is trading well below its 200-day moving average and has fallen 10.8% over the last month, indicating a clear downtrend and negative momentum. Being significantly under the 200-day moving average typically reflects sustained selling pressure and weak investor confidence. Without evidence of a reversal pattern or oversold technical indicators like RSI, the setup remains technically bearish in the near term.

Current price of $165.00 is materially below the 200-day moving average of $213.22, a classic sign of a prevailing downtrend and long-term technical weakness.
A 10.8% decline over the last month points to accelerating negative momentum, suggesting recent sentiment has turned more cautious or risk-off toward the stock.
Trading below the 200-day moving average often acts as overhead resistance, meaning any rebound may face selling pressure until the price can sustainably reclaim that level.

Alternative Data Signals

neutral

Alternative data for HUTCHMED (China) Limited is modest in scale and mixed in direction. Web traffic is relatively low at about 10,021 visitors per month, implying limited retail/investor or customer engagement online, but job openings are up 25% month over month, suggesting some operational or growth initiatives. Social media presence is very small and only inching higher, offering little evidence of strong brand or investor buzz.

Estimated web traffic of 10,021 visitors per month is low for a listed company, indicating limited digital footprint and weak retail or stakeholder engagement via the website.
Job openings at 10, up 25% month over month, point to incremental hiring and potential expansion in specific functions (e.g., R&D, clinical, or commercial), which is a mildly positive operational signal.
Social media audience is minimal at 278 Twitter/X followers, with only 0.4% growth over 90 days, suggesting very limited online visibility and little momentum in investor or public interest.

Conclusion

bearish

Overall, the setup for HUTCHMED (China) Limited appears bearish, driven primarily by weak price action and a clear technical downtrend. While the company is profitable on an EPS basis and the headline PE ratio appears low, the market is assigning a steep discount, likely reflecting concerns about growth, risk, or earnings quality. Alternative data are mixed but not strong enough to offset the negative technical picture.

Technical indicators dominate the near-term view: trading well below the 200-day moving average with a double-digit monthly decline supports a bearish stance.
Fundamentals and alternative data show a profitable but modestly growing operation with limited digital and social presence, which does not yet provide a strong counterweight to the negative market sentiment.

AI Score

Hold

Alternative6

Fundamental7

Technical3

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold HCM.L in your mock portfolio yet.